NICE Guidance

NICE recommends Medtronic integrated sensor-augmented insulin pump as the only therapy system to manage glucose levels in type 1 diabetes


  • The NICE guidance [2] reviewed two sensor-augmented insulin pump therapy systems and recommends the MiniMed Paradigm Veo system for managing glucose levels in people with Type 1 diabetes.[i]
  • The MiniMed Paradigm Veo* sensor-augmented insulin pump therapy system can help to protect against severe hypoglycaemia in people with Type 1 diabetes by continuously monitoring glucose levels.[i]
  • NICE recognised that in 2015, Medtronic launched a successor system, the MiniMed 640G**, which could be used in place of other reactive continuous glucose monitoring and insulin pump systems.[ii]
  • Nearly 60,000 hospital admissions last year were as a result of severe hypoglycaemic attacks in people with Type 1 diabetes, costing the NHS approximately £55 million.[iii]
  • Approximately one in three people with Type 1 diabetes have problematic hypoglycaemia, which can impact many aspects of daily life and result in substantial anxiety.[i]
  • Up to 5,000 people with Type 1 diabetes could benefit from using continuous glucose monitoring (CGM).[i]
  • NICE concluded that the adoption of Medtronic technology has the potential to save a UK health system £1,500 per person per year.[i]

Download below the Medtronic news-release regarding the NICE recommendation:

> NICE Guidance Press Release by Medtronic [3]


For any related inquiries, please complete the Contact form


For any PRESS inquiries, please contact Rebecca Fancini or Claudia Bolouri
Rebecca Fancini Claudia Bolouri
Communications Manager Senior Account Manager
Medtronic Ltd Ketchum
Tel: +44 (0)1923 205149 Tel: +44 (0)203 7556434



By submitting this form, I agree to the terms of use. [6]

This question is for testing whether you are a human visitor and to prevent automated spam submissions.